TOI vs. VRDN, AVAH, PNTG, CDNA, AGL, FLGT, LFMD, TALK, INNV, and EHAB
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include Viridian Therapeutics (VRDN), Aveanna Healthcare (AVAH), The Pennant Group (PNTG), CareDx (CDNA), agilon health (AGL), Fulgent Genetics (FLGT), LifeMD (LFMD), Talkspace (TALK), InnovAge (INNV), and Enhabit (EHAB). These companies are all part of the "healthcare" industry.
Oncology Institute vs. Its Competitors
Viridian Therapeutics (NASDAQ:VRDN) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
Oncology Institute has a net margin of -17.63% compared to Viridian Therapeutics' net margin of -85,127.16%. Viridian Therapeutics' return on equity of -70.12% beat Oncology Institute's return on equity.
In the previous week, Oncology Institute had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for Oncology Institute and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.82 beat Oncology Institute's score of 0.49 indicating that Viridian Therapeutics is being referred to more favorably in the media.
Oncology Institute has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
36.9% of Oncology Institute shares are owned by institutional investors. 1.6% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Viridian Therapeutics presently has a consensus price target of $37.56, suggesting a potential upside of 139.67%. Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 164.15%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts plainly believe Oncology Institute is more favorable than Viridian Therapeutics.
Viridian Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.
Viridian Therapeutics received 75 more outperform votes than Oncology Institute when rated by MarketBeat users. Likewise, 79.21% of users gave Viridian Therapeutics an outperform vote while only 71.43% of users gave Oncology Institute an outperform vote.
Summary
Oncology Institute beats Viridian Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
This page (NASDAQ:TOI) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy TOI Stock Free TOI Stock Alerts